

Intensive Insulin Therapy as the Primary Treatment for Type 2 Diabetes

Lubaina S. Presswala, BS, and Jay H. Shubrook, DO, FACP

Presentation

A 47-year-old obese, white man with a history of prediabetes and dyslipidemia presented to his primary care physician for a routine follow-up. He weighed 285.6 lb, and his BMI was 39.8 kg/m². He was a smoker with a 30-pack-year history and drank Mountain Dew soft drinks all through the day. He occasionally consumed alcohol, exercised rarely, and had no history of illicit drug use.

His medications included Naproxen, 500 mg, and Flexeril, 10 mg, for use as needed. He had an extensive family history of type 2 diabetes and hypertension. He had a normal physical examination except for truncal obesity. His most recent laboratory values included a random glucose of 264 mg/dl, total cholesterol of 225 mg/dl, triglycerides of 459 mg/dl, HDL of 27 mg/dl, and LDL of 144 mg/dl. His A1C at this visit was too high to be recorded, and his C-peptide level was 2.6 ng/ml.

We informed him of the new findings and presented him with numerous treatment options. He

agreed to initiate lifestyle modifications with diet and exercise but was not keen on taking two or three oral medications. Thus, he opted to initiate his treatment with intensive insulin therapy to get back in control. He completed diabetes education and was instructed on self-monitoring of blood glucose (SMBG), use of an insulin pen, and recognition of the signs and symptoms of hyper- and hypoglycemia.

He was started on basal-bolus analog insulin therapy, including glargine, 16 units daily, and aspart, fixed dose of 6 units/meal. He was also advised to stop drinking Mountain Dew. His initial glucose values are shown in Table 1. His recommended blood glucose targets were fasting 80–150 mg/dl and random 80–120 mg/dl. Any reading < 70 mg/dl was considered a mild hypoglycemic event, and those < 60 mg/dl were considered severe hypoglycemia.

For the first 12 days, he was globally hyperglycemic, with highest readings at bedtime. Glargine was increased to 20 units daily, and

aspart was continued at 6 units/meal. His glucose values for the following 2 weeks are shown in Table 2.

His bedtime glucose readings improved tremendously, with more fasting and random glucose readings within the target ranges. He had discontinued Mountain Dew. There was no change made in insulin dosage for the next 2 weeks. His blood glucose readings for weeks 4 and 5 are presented in Table 3.

At the end of week 5, we increased his insulin to 22 units of glargine daily and 8 units of aspart before dinner. Aspart was continued at 6 units before breakfast and lunch. Glucose values with this insulin regimen are shown in Table 4.

As evident from the blood glucose readings, all his fasting blood glucose results were < 150 mg/dl, most of his random glucose readings fit the target range of 80–120 mg/dl, and his bedtime readings showed remarkable improvement since his initial range of 250–350 mg/dl with intensive insulin therapy.

At the end of week 7, he was advised to discontinue aspart and

Table 1. Initial SMBG Results (mg/dl) With Intensive Insulin Regimen

	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12
Fasting	—	—	203	—	196	215	227	222	184	213	—	—
Lunch	—	204	—	182	—	—	—	211	—	190	—	—
Dinner	225	233	322	256	174	149	301	248	—	169	—	264
Bedtime	293	285	296	306	341	303	260	311	226	260	—	168

Table 2. SMBG Results (mg/dl) for Weeks 2 and 3

	Day 13	Day 14	Day 15	Day 16	Day 17	Day 18	Day 19	Day 20	Day 21	Day 22	Day 23	Day 24	Day 25	Day 26
Fasting	162	163	165	193	159	132	168	141	155	118	141	134	160	173
Lunch	—	136	—	—	140	131	115	104	174	—	138	—	166	112
Dinner	130	279	123	127	172	142	121	114	260	95	— -	114	89	111
Bedtime	294	293	280	158	-	270	223	152	192	216	150	199	267	260

Table 3. SMBG Results (mg/dl) for Weeks 4 and 5

	Day 27	Day 28	Day 29	Day 30	Day 31	Day 32	Day 33	Day 34	Day 35	Day 36	Day 37	Day 38	Day 39	Day 40
Fasting	145	124	149	—	148	—	174	147	141	142	—	146	135	103
Lunch	106	—	200	162	—	—	131	122	—	—	—	—	119	117
Dinner	94	108	110	110	—	131	105	—	113	—	—	126	110	98
Bedtime	250	182	-	-	-	240	250	249	119	-	-	183	254	-

Table 4. SMBG Results (mg/dl) for Weeks 6 and 7

	Day 41	Day 42	Day 43	Day 44	Day 45	Day 46	Day 47	Day 48	Day 49	Day 50	Day 51	Day 52	Day 53	Day 54
Fasting	134	123	119	134	95	130	111	113	120	107	109	109	112	117
Lunch	131	—	126	—	—	110	76	95	86	83	82	89	90	—
Dinner	83	107	125	86	88	116	116	108	105	85	82	85	113	85
Bedtime	96	137	105	89	-	151	179	128	128	88	113	79	108	-

slowly down-titrate glargine by 4 units every week for 5 weeks. His total time on insulin was 12 weeks. He never experienced a hypoglycemic event throughout the treatment therapy.

His A1C after 15 weeks of intensive insulin therapy was 6.4%. At his annual follow-up, his A1C was 6.0%, and his C-peptide level increased to 3.4 ng/ml. Additionally, his laboratory values included total cholesterol of 186 mg/dl, triglycerides of 197 mg/dl, HDL of 30 mg/dl, and LDL of 116 mg/dl without the use of any lipid-lowering medications.

At his most recent visit, 27 months after completing intensive insulin therapy, his A1C was 6.7% without any additional exogenous insulin or oral diabetes medications. He had no complaints except for recent weight gain he attributed to stress related to being laid off from work.

Questions

1. What is the benefit of recommending intensive insulin therapy as primary treatment for type 2 diabetes?
2. Is there additional evidence supporting the use of insulin therapy as a primary treatment?

3. What determines insulin titration, and how does it affect A1C values over time?

4. What are the potential short-term and long-term benefits of early insulin therapy with disease progression?

Commentary

The natural history of type 2 diabetes demonstrates the relentless decline of β -cell function over time.¹ The progressive defects in insulin secretion and action lead to uncontrolled hyperglycemia, further aggravating insulin resistance and impairing β -cell function.¹

The American Diabetes Association has historically recommended incorporating lifestyle modification followed by oral antidiabetic medications for diabetes treatment and supplementing insulin for those who fail initial therapy.² By the time diabetes is diagnosed, β -cell function and mass have declined by 50%.³ With the progression of the disease, there is a continuous decrease in β -cell mass because of increased apoptosis that results in absolute insulin deficiency.³ When insulin is needed, < 10% of β -cells are functioning.

Thus, the objective of intervening with intensive insulin therapy early in the disease is to rest the β -cells and possibly preserve the retardation of cell function over time. This can potentially restore endogenous insulin production and induce remission (maintenance of normoglycemia using no medication) in diabetes. The exact effects of insulin treatment on β -cell function are not fully understood.⁴ It is believed to reduce glucotoxicity and prevent hyperstimulation of pancreatic insulin release and therefore lay the foundation for improved β -cell function.³

In a study by Ryan et al.,¹ 16 newly diagnosed type 2 diabetic patients received 2–3 weeks of intensive insulin therapy and were followed for 1 year. All 16 patients presented with fasting serum glucose levels > 200 mg/dl at the time of initial diagnosis. Regular insulin was initiated at a dose of 5 units before meals, and NPH was given at 10–15 units at bedtime.

Fasting serum glucose levels decreased to 125 ± 8 mg/dl after insulin therapy ($P < 0.01$) and remained improved at 1 year. After 1 year, all subjects had reasonable glycemic control with a mean A1C of

$6.6 \pm 0.3\%$. Seven patients remained off medication, six were on glyburide, two were on a combination of glyburide and metformin, and one was on insulin after the initial 3 weeks of therapy. These results demonstrate the success of rapidly correcting serum glucose levels in most patients with newly diagnosed diabetes.

In this case study, basal-bolus analog insulin therapy was used as the primary treatment for type 2 diabetes. Insulin was titrated based on SMBG results to gain tighter glucose control. This patient had a prolonged reduction in A1C for as long as 27 months after insulin therapy without any oral medications or exogenous insulin.

This case study supports the use of aggressive insulin early in the disease process to gain tighter glucose control, possibly preserve β -cell function and mass, and potentially induce remission (even if only temporarily) over time. The potential short-term benefits are not limited to lowering hyperglycemia, but also include reducing free fatty acid levels, lipid levels, and endogenous glucose production. This case study is the first, so far, to use outpatient intensive insulin therapy as the primary treatment for type 2 diabetes.

Clinical Pearls

- Short-term insulin therapy as an initial treatment of type 2 diabetes can lead to significant improvement in A1C and lipid values.
- No severe hypoglycemia was observed throughout the course of this treatment.
- Primary treatment for type 2 diabetes using intensive insulin has the potential of quickly attaining and maintaining recommended A1C values of < 7%² or < 6.5%.⁵
- Sustained euglycemia over time

without any oral antidiabetic medications or exogenous insulin after intensive insulin therapy is known as the “legacy effect.”

- Benefits of this approach include reducing hyperglycemia, preserving β -cell function, and possibly restoring normal insulin secretion for lasting glucose control.

REFERENCES

- ¹Ryan EA, Imes S, Wallace C: Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. *Diabetes Care* 27:1028–1032, 2004
- ²Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman R, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. *Diabetes Care* 32:193–203, 2009
- ³Rolla A: The pathophysiological basis for intensive insulin replacement. *Int J Obes Relat Metab Disorder* 28 (Suppl. 2):S3–S7, 2004
- ⁴Shubrook JH, Jones SA: Basal-bolus analogue insulin therapy as initial treatment of type 2 diabetes mellitus: a case series. *Insulin* 5:100–105, 2010
- ⁵Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebowitz H, Levy P, Moghissi ES, Schwartz SS: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract* 15:540–559, 2009

Lubaina S. Presswala, BS, is a third-year medical student at Ohio University Heritage College of Osteopathic Medicine in Athens, Ohio. Jay H. Shubrook, DO, FACP, is an associate professor of family medicine and director of the diabetes fellowship program at the same institution.

Note of disclosure: Dr. Shubrook has served on an advisory committee to sanofi-aventis and has received research support from sanofi-aventis and Eli Lilly. Both companies market insulin products for the treatment of diabetes.